Karyopharm Therapeutics Inc. (KPTI)

NASDAQ: KPTI · Real-Time Price · USD

10.07

+0.04 (0.40%)

At close: Feb 24, 2026, 4:00 PM EST

10.27

+0.20 (1.99%)

Pre-market: Feb 25, 2026, 8:03 AM EST

Karyopharm Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	146.07	145.24	146.03	157.07	209.82
Revenue Growth (YoY)	0.57%	-0.55%	-7.03%	-25.14%	94.12%
Cost of Revenue	131.57	149.24	143.69	153.88	3.4
Gross Profit	14.5	-4	2.34	3.2	206.42
Selling, General & Admin	105.21	115.44	131.88	145.4	143.85
Research & Development	-	-	-	-	160.84
Operating Expenses	105.21	115.44	131.88	145.4	304.69
Operating Income	-90.71	-119.44	-129.54	-142.2	-98.27
Interest Expense	-45.85	-37.42	-23.82	-25	-26.05
Interest & Investment Income	2.77	7.4	10.94	2.36	0.58
Other Non Operating Income (Expenses)	0.15	28.4	-0.36	-0.08	-0.09
EBT Excluding Unusual Items	-133.63	-121.07	-142.78	-164.92	-123.82
Other Unusual Items	-62.37	44.7	-	-	-
Pretax Income	-196	-76.37	-142.78	-164.92	-123.82
Income Tax Expense	0.04	0.06	0.32	0.37	0.27
Net Income	-196.04	-76.42	-143.1	-165.29	-124.09
Net Income to Common	-196.04	-76.42	-143.1	-165.29	-124.09
Shares Outstanding (Basic)	11	8	8	5	5
Shares Outstanding (Diluted)	11	8	8	5	5
Shares Change (YoY)	29.33%	11.02%	39.54%	8.85%	4.41%
EPS (Basic)	-17.93	-9.41	-18.79	-30.28	-24.75
EPS (Diluted)	-17.93	-14.00	-18.79	-30.30	-24.75
Free Cash Flow	-75.37	-127.63	-92.72	-149.67	-107.33
Free Cash Flow Per Share	-6.89	-15.10	-12.18	-27.42	-21.40
Gross Margin	9.93%	-2.76%	1.60%	2.04%	98.38%
Operating Margin	-62.10%	-82.24%	-88.71%	-90.53%	-46.84%
Profit Margin	-134.21%	-52.62%	-97.99%	-105.23%	-59.14%
Free Cash Flow Margin	-51.60%	-87.88%	-63.50%	-95.29%	-51.15%
EBITDA	-90.41	-119.1	-129.01	-141.58	-97.48
EBITDA Margin	-61.90%	-82.01%	-88.34%	-90.14%	-46.46%
D&A For EBITDA	0.3	0.34	0.53	0.62	0.79
EBIT	-90.71	-119.44	-129.54	-142.2	-98.27
EBIT Margin	-62.10%	-82.24%	-88.71%	-90.53%	-46.84%
Revenue as Reported	146.07	145.24	146.03	157.07	209.82

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q